《新股消息》科濟藥業遞主板上市申請 傳計劃籌3億美元
內地臨床階段的生物製藥公司科濟藥業已遞交主板上市申請,聯席保薦人為高盛及瑞銀,據路透旗下IFR引述消息指,公司計劃籌3億美元。
目前,科濟藥業並無獲批准商業化銷售的產品及尚未從產品銷售產生任何收益,而去年度其經營虧損為3.27億元人民幣,幾乎全部經營虧損都是由研發開支及行政開支所致,預期在至少未來幾年會產生重大開支及經營虧損,因為公司需要進一步進行臨床前研究與開發、繼續進行候選產品的臨床開發、就候選產品尋求監管批准、對管線產品進行商業化以及增聘必要人員以經營其業務。(el/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.